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Introduction
Improved means of transportation, economic prosperity and changing preferences, and needs of the population have boosted mountain tourism over the course of the last few years [1] . Every year, millions of people are traveling to high-altitude regions of the world exposing themselves to hypobaric hypoxia [2] . It may promote dyspnea and exercise limitation [3] , sleep disturbances [4] , and altitude-related illness [5] . In healthy individuals, we have observed sleep and breathing disturbances already at relatively moderate altitudes of 1650 and 2590 m, which corresponds to the elevation of many tourist destinations worldwide [6] . More severe alterations in sleep structure including a reduction in slow-wave sleep, sleep efficiency, and pronounced high-altitude periodic breathing occur in unacclimatized mountaineers at higher altitudes [7, 8] .
Chronic obstructive pulmonary disease (COPD) is highly prevalent in the general population and a major health problem worldwide, being one of the leading causes of mortality and morbidity [9] . Many patients with COPD suffer from an impaired pulmonary gas exchange with hypoxemia, disturbances of control of breathing, and disordered sleep already at sea level [10] [11] [12] . This may make them susceptible to altitude-related adverse health effects including more pronounced alterations in sleep and nocturnal breathing. However, this has not been appropriately studied. Therefore, robust scientific data to counsel patients with COPD traveling to altitude are needed. The current randomized study was designed to quantify the nocturnal oxygenation, breathing pattern, and sleep in patients with COPD living near sea level during a stay in mountain villages at moderate altitude. We evaluated the hypothesis that the patients with COPD would experience nocturnal hypoxemia, periodic breathing with central apneas/hypopneas, and sleep disturbances during their altitude sojourn.
Methods

Study design and setting
This was a randomized crossover trial evaluating effects of altitude exposure on nocturnal oxygenation, breathing, and sleep in patients with COPD. From June to October 2013, participants underwent baseline studies at low altitude during 2 days (Zurich, 490 m, 1608 ft, barometric pressure [PB] 719 Torr) and at moderate altitude during 4 days in Swiss alpine villages, 2 days at Davos Clavadel (1650 m, 5413 ft, PB 628 Torr), and 2 days at Davos Jakobshorn (2590 m, 8497 ft, PB 562 Torr). At all locations, sleep studies and daytime evaluations were performed in quiet single rooms. The protocol was approved by the Cantonal Ethics Committee Zurich and patients gave written informed consent. The current study was performed in conjunction with investigations on exercise performance [13, 14] , but, except for some baseline characteristics, arterial blood gas analyses, and acute mountain sickness scores, the data focused on sleep and vigilance presented here have not been published. The trial is registered at www.ClinicalTrials.gov: NCT01870830.
Participants
Patients with COPD with GOLD grade 2-3, diagnosed according to the Global Initiative for Obstructive Lung Disease (GOLD) guidelines [9] affecting respiratory center drive, and no exposure to altitudes >1500 m for >2 days within the last 4 weeks before the study were permitted. For safety reasons, patients with severe hypoxemia (pulse oximetry, SpO 2 <80% for ≥30 min), or with any clinically relevant adverse effect of altitude or intercurrent illness were treated and transported to lower altitude as appropriate.
Randomization and interventions
The altitude exposure sequence was according to a balanced block design with four different altitude profiles including 2 days/nights sojourns at each of the three altitude levels 490 m (low), 1650 m (intermediate), and 2590 m (high). Accordingly, participants were randomized to four groups with profiles A-D: group A: low-intermediate-high; group B: low-high-intermediate; group C: intermediate-high-low; and group D: high-intermediate-low. Participants were randomized by letting them choose an available study time slot without being aware of the corresponding altitude exposure sequence. Participants traveled by train and cars between Zurich and Davos Clavadel and by cable car between Davos train station and Davos Jakobshorn.
Measurements
Sleep studies
Polysomnography was performed in the first night at each location as described previously (Alice 5, Philips Respironics, Zofingen, Switzerland) [15] . Electroencephalogram (derivations C3A2, C4A1, F1A2, F2A1, O1A2, O2A1), bilateral electro-oculogram, submental electromyogram, calibrated respiratory inductance plethysmography [16] , diaphragmatic surface EMG [17] , transcutaneous capnography (PtcCO 2 , TOSCA, Linde Medical Sensors AG, Basel, Switzerland) [18] , and nasal pressure swings were recorded [19] . Respiratory polygraphy including all measurements of polysomnography with exception of neurophysiological channels was performed in the second night at each location. Sleep stages and arousals were scored according to Rechtschaffen and Kales [20] and the American Academy of Sleep Medicine [21] . Independent arousal scoring by two blinded investigators revealed close agreement with a nonsignificant bias (mean difference) of 1 arousal/ hr, and 95% confidence interval (limits of agreement) of −7.8 to +8.8 arousals/hr. Apneas/hypopneas were defined as a reduction of nasal pressure swings or the inductive plethysmographic sum signal to <10% and <50% of the baseline, respectively, during >10 s [22, 23] . Transient reductions in breathing amplitude to <50% baseline for 5-10 s were also scored as apneas/hypopneas if they occurred as part of a periodic breathing pattern with hyperventilation alternating with central apneas/hypopneas for at least three consecutive cycles. Obstructive apneas/hypopneas were identified by rib cage and abdominal asynchrony and persistent or increasing diaphragmatic EMG activity. Central apneas/hypopneas were identified by absent rib cage-abdominal asynchrony, no signs of inspiratory flow limitations (no flattening of nasal pressure contour), and reduced or absent diaphragmatic EMG activity [23] . Apneas/hypopneas that showed an initial central portion and subsequent characteristics suggesting upper airway obstruction were classified as mixed apneas/hypopneas. The apnea-hypopnea index (AHI) was computed as the number of events both per hour of total sleep time (TST) and per hour of time in bed (TIB) to allow comparisons between nights with and without neurophysiological recordings (nights 1 and 2 at each location). The oxygen desaturation index (ODI, >3% dips) was computed as the number of events per TIB. ECG analysis included heart rate and extra beats.
Morning examinations performed between 9 and 10 am comprised questionnaires to assess current sleepiness (Karolinska sleepiness scale ranging from 1 (very alert) to 9 (very sleepy, fighting sleep) [24] and the estimated time spent awake during the previous night [15] . Acute mountain sickness was evaluated by the Environmental Symptoms Questionnaire cerebral score (AMSc) comprising 11 questions on symptoms rated from 0 (not at all) to 5 (extreme). The weighted sum of responses ranges from 0 to 5. Scores of ≥0.7 are considered to reflect clinically relevant AMS [25] . An arterial blood gas analysis was also performed during wakefulness (RAPIDPOINT 405, Siemens, Bad Naunheim, GE). The psychomotor vigilance test (PVT) was performed while patients were sitting comfortably on a chair in a quiet room. They had to press a button on a hand-held device in response to a light on the device flashing at unbalanced intervals [26] . Median reaction time was recorded. During the trail making test A, patients had to connect numbers from 1 to 90 printed on a paper as fast as they could with a pen [27] . The time until they reached the number "90" was measured.
Outcomes
Primary outcomes were the mean nocturnal oxygen saturation and the AHI. Secondary outcomes were other polysomnographic indices, symptoms, and daytime performance.
Sample size
To detect differences between altitudes in the mean nocturnal oxygen saturation of 2% (SD 4) and in the AHI of 10/hr (SD 20) [15] with a two-sided significance level of 0.05 and a power of 80%, the required sample size was 32 participants.
Blinding
Investigators were blinded in regard to the altitude of recorded data until all analyses were completed.
Statistical analysis
Analysis of data in this clinical/physiological study was performed according to the per protocol principle with data from patients with complete data sets. As most outcome variables were not normally distributed, data are summarized as medians (quartiles). The effects of altitude and time at any altitude were evaluated by Friedman ANOVA followed by Wilcoxon-matched pair tests applying a Bonferroni correction for multiple comparisons if p ANOVA was significant. In addition, median differences and 95% confidence intervals (95% CI) of altitude-induced changes were computed. Univariable and multivariable regression analyses were employed to assess effects of altitude on the AHI and the nocturnal oxygen saturation while controlling for various potential confounders. The effect of apneas/hypopneas and of altitude on arousals, and the effect of altitude on the NREM and REM sleep-related increase in PCO 2 were also evaluated by multivariable regression analyses. Variables with p <0.2 in univariable analyses were maintained in the multivariable model. Statistical significance was assumed at p <0.05.
Results
Of 191 screened patients, 40 met the inclusion criteria and were randomized. Two study participants withdrew consent after baseline examination in Zurich and one refused to ascend to 2590 m because of insomnia at 1650 m. According to predefined safety criteria, six participants (five at 2590 m and one at 1650 m) were treated with supplemental oxygen during part of a night because of severe hypoxemia (nocturnal SpO 2 <80% for ≥30 min) or because of subjective discomfort. They were able to remain at altitude and felt well thereafter. Their data were excluded from the analysis. Data from 32 participants were analyzed ( Figure 1 ). Their baseline characteristics are summarized in Table 1 .
Sleep studies
Results are numerically summarized for each altitude in Table 2 and altitude-induced changes are illustrated in Figures 2 and 3. Nocturnal SpO 2 was significantly reduced at 1650 m and even more at 2590 m compared with 490 m. Compared with the nights at 490 m, the time spent with SpO 2 <90% increased by a median (95% CI) of 37% (19 to 54) and 37% (22 to 62) in the first and second nights at 1650 m and by 74% (58 to 89) and 77% (51 to 89) in the first and second nights at 2590 m. The median AHI at 490 m averaged over the two nights was 11.9/hr TIB with mainly obstructive events and it increased during the first night at 1650 m to 23.3/hr TIB and to 39.5/hr TIB (58.5/hr TST) at 2590 m, mainly due to central events ( Table 2 , Figures 2 and 3 ). Consistent with data presentation in previous studies [4, 7, 15, 23] and for clarity of presentation, the rare mixed apneas/hyponeas are reported together with the obstructive apneas/hypopneas in Table 2 . A more detailed account of the different types of apneas and hypopneas is presented in Supplementary Table 1 . The most common types of events that increased from very low values at 490 m to high values at the higher altitudes were central hypopneas and apneas. Conversely, obstructive apneas and hypopneas were more common than central events at 490 m but did not change with increasing altitude while mixed apneas/hypopneas were rare at all three altitudes (Figure 2 , Supplementary Table 1 ). The apnea/hypopnea duration progressively decreased with increasing altitude (Supplementary Table 1 ). When compared with the first night at corresponding altitude, there was no significant change of SpO 2 and AHI (TIB) in the second night (Table 2) .
Sleep stage-specific evaluation of the breathing pattern revealed an increase in the total AHI during both NREM and REM sleep at the higher altitudes (Table 3 ). The increase during NREM sleep was mainly due to emergence of central apneas/hypopneas, whereas the increase during REM sleep was due to central and obstructive apneas/hypopneas. The PtcCO 2 decreased with increasing altitude both in NREM and REM sleep ( Figure 3 , Table 3 ). To evaluate the effect of altitude on the normal sleeprelated increase in PaCO 2 from wakefulness to NREM and REM sleep, the difference between PtcCO 2 during NREM and REM, respectively, minus PaCO 2 measured during wakefulness was entered as a dependent variable into a multivariable regression analysis (for details see Supplementary Table 2 ). This revealed mean NREM and REM sleep-related increases in PCO 2 at 490 m of 6.8 and 7.8 mmHg (p <0.001, both instances); at 1650 m, the NREM and REM sleep-related increases in PCO 2 were 5.7 and 6.6 mmHg (p = n.s. vs. corresponding values at 490 m); and at 2590 m, the corresponding increases in PCO 2 were less pronounced, i.e. 3.6 and 5.1 mmHg (p <0.05 vs. 490 m, both instances).
Sleep duration and structure were impaired at 2590 m as reflected in a reduced sleep efficiency of 59%, a longer time in wakefulness after sleep onset and a slight reduction in slowwave sleep (stages 3 and 4) when compared with 490 m (Figure 3 , Table 2 ). The total arousal index was slightly increased at 2590 m compared with the baseline values at 490 m which was due 
Values are medians (quartiles) and numbers (n, %). central apnea/hypopnea-related arousals while the nonapnea/hypopnea-related arousals remained unchanged ( Table 4 ). Conversely, no significant association was found among the change in altitude and the nonrespiratory event-related arousals (Supplementary Table 4) . Compared with 490 m, heart rate increased at higher altitudes and we observed an increased incidence of ventricular arrhythmias in the first night at 2590 m compared with the night at 490 m ( Table 2) .
To investigate the determinants of the AHI at 1650 and 2590 m, univariable-and multivariable-ordered logistic regression analysis was performed. It confirmed a positive association of the AHI with altitude when controlled for age, sex, body mass index, PtcCO 2 , and AHI at low altitude (490 m) (Supplementary Table 5 ). A similar analysis with mean nocturnal SpO 2 at the higher altitudes (1650 and 2590 m) as a dependent variable revealed that altitude, SpO 2 , and AHI at 490 m were significant independent predictors while the FEV1 % predicted was not (Supplementary Table 6 ).
Daytime evaluation
Patients reported to feel fairly alert at all altitudes as indicated in the median Karolinska sleepiness score of 2-3 (Table 4) . But in the morning after the first night of the stay at 2590 m, the Karolinska scores indicated a subtle reduction in alertness when compared with 490 m. The estimated time of the night spent awake increased, especially during the first night at 2590 m. No impairment in PVT reaction time or in the trail making performance was observed at the higher altitudes when compared with 490 m. Patients did not report a higher degree of dyspnea at 1650 and 2590 m compared with 490 m but the AMSc score in the morning after the first night at 2590 m was slightly increased reflecting mild symptoms of AMS. The arterial blood gas analysis revealed a progressive hypoxemia and hypocapnia with increasing altitude (Table 4 ).
Discussion
The current randomized trial in patients with moderate to severe COPD living near sea level demonstrates that ascent to 1650 and 2590 m resulted in progressive hypoxemia associated with predominantly central sleep apnea, disturbed sleep with a reduced sleep efficiency and slow-wave sleep, and more ventricular extra beats. Patients reported a slight reduction in perceived alertness in the morning after the first night of the stay at 2590 m compared with the morning at 490 m. These novel findings represent long-needed information to counsel patients with COPD traveling to altitude. In healthy lowlanders with a median age of 24 years undergoing studies according to a similar design and setting as that of the current study, i.e., ascending rapidly to 1630 and 2590 m, we previously reported that exposure to mild hypobaric hypoxia induced nocturnal hypoxemia, periodic breathing with central apneas/hypopneas, and sleep disturbances like those in the current patients with COPD although the changes were much less pronounced [6] . Although patients with COPD in their first night at 2590 m spent a median of 93%TIB with SpO 2 <90% and an AHI of 39.5/hr (Table 2) , the corresponding values in healthy individuals were 36%TIB and 13.1/hr. The rigorous appraisal of the COPD-specific changes in sleep and breathing at altitude in the current study is hampered by the lack of an age-matched healthy control group. Nevertheless, the degree of nocturnal hypoxemia at low altitude, one of the markers of gas exchange impairment in the patients with COPD, was a significant, independent predictor of hypoxemia at higher altitudes in multivariable regression analysis while the degree of airflow obstruction and age were not (Supplementary Tables 5 and 6 ). In lowlanders with untreated obstructive sleep apnea syndrome (median age 62 years), we observed that the patients spent a considerable time with SpO 2 <90% (i.e. 76% of TIB) at 2590 m and their AHI was higher at 2590 m (90.0/hr) than at 490 m (47.5/hr) due to frequent central events (central AHI 51.3/hr) in addition to the numerous obstructive apneas/hypopneas that were also present during low altitude baseline studies at 490 m [23] .
Although some studies have suggested an association of COPD with sleep apnea [28, 29] , this has not been confirmed in other investigations controlling for confounding factors including age, body mass index, among others [30] . Differences in patient characteristics (i.e. degree of daytime hypoxemia and prevalence of hypercapnia), in the study setting, and in measurement techniques may account for some of these discrepancies. In the current study, people with pre-existing known or suspected sleep apnea were excluded from participation. Accordingly, the total AHI at 490 m was low (11.2/hr TIB, Table 2 ) and not higher than values reported for participants of similar age from the general population [31] . The obstructive AHI did not increase during the stay at the higher altitudes and the breathing instability associated with hypocapnia was due to central apneas/hypopneas (Table 2, Figure 2 ). This was consistent with a reduction in the CO 2 reserve due to the hypoxic stimulation of ventilation reflected in the reduced nocturnal PtcCO 2 (Tables 2 and 3 ) and in the daytime PaCO 2 (Table 4) [7, 32] . Compared with healthy individuals, patients with COPD may have an increased neural ventilatory drive and thus a high controller gain during wakefulness and sleep already at sea level [33] that predisposes to ventilatory instability [34] [35] [36] . The shorter apnea/hypopnea duration (Supplementary Table 1) , the lower PtcCO 2 and PaCO 2 at the higher altitudes of 1650 and 2590 m compared with 490 m (Table 2) , and the less pronounced increase in PCO 2 from wakefulness to NREM and REM sleep at 2590 vs. 490 m (Supplementary Table 2 ) are consistent with the assumption that the greater propensity for central sleep apnea was related to an enhanced neural respiratory drive at higher altitudes. During REM sleep, a predominant increase in obstructive rather than central apneas/hypopneas was observed at the higher altitudes (Table 3 ) that may suggest an impaired control of upper airway patency in the presence of rigorous inspiratory efforts resulting in a reduced efficacy of neural inspiratory drive and thus higher PtcCO 2 during REM compared with NREM sleep (Table 3) [33, 34] . The additional hypoxic ventilatory stimulation during altitude exposure together with circulatory disturbances in some patients with arterial hypertension and coronary heart disease ( Table 1 ) associated with subclinical, mild heart failure may have resulted in an excessively high controller gain and a prolongation of circulatory time [37, 38] . This may have predisposed the patients with COPD in the current study to a greater increase in central apneas/hypopneas when ascending to 2590 m compared with healthy, young individuals [6] . In studies performed near sea level, patients with COPD have been reported to suffer from poor self-reported sleep quality with insomnia, restlessness, and frequent awakenings [39] that were reflected in a reduced sleep efficiency of 66% and a reduction in REM sleep of 13% during polysomnography. Daytime hypoxemia (reduced PaO 2 ) independently predicted the reduction in the sleep efficiency [11, 40] . In participants of the Sleep Heart Study, severity of airflow obstruction (FEV1 % predicted) was correlated with reduced sleep efficiency even in individuals without sleep apnea [30] . In the current study in patients with moderate to severe COPD, the sleep analysis at 490 m revealed a low sleep efficiency (72%) but similar fractions of NREM 3 + 4 and REM sleep (20% and 18% of TST) to corresponding values in participants without airflow obstruction and sleep apnea in the Sleep Heart Study (16% and 20%TST, respectively) [30] . To the best of our knowledge, no data on nocturnal breathing pattern and sleep in patients with COPD at moderate altitude have been published. The current results demonstrate that exposure to hypobaric hypoxia resulted in a reduction in TST, a reduced sleep efficiency (59% in the first night at 2590 m), a greater amount of wakefulness after sleep onset, and reduced deep sleep (NREM 3 and 4) at 2590 vs. 490 m ( Table 2) . Reductions in NREM stages 3 and 4 have been previously observed along with a reduction in slow-wave power in healthy individuals ascending from lowlands to 2590 m [41, 42] . Together with the reduced sleep efficiency reported in hypoxemic patients with COPD near sea level [11] and studies in rats exposed to hypobaric hypoxia showing a reduced sleep duration associated with alterations in brain neurotransmitters involved in sleep/wakefulness regulation [43] , these findings may suggest an adverse effect of hypoxemia on sleep consolidation possibly via an effect of hypoxia on central control of sleep/wakefulness. In the current patients with COPD, the association of the arousal index (either total or apnea/hypopnea-related arousal index) with the central AHI was relatively weak (on average, 1 of 3.6 to 1 of 3.8 central apneas/hypopneas were arousal-associated; Figure 2 , Supplementary Tables 3 and  4) . These findings were consistent with an only moderate association of central apneas/hypopneas with arousals during highaltitude periodic breathing in healthy individuals [6, 7, 44] and in lowlanders with untreated obstructive sleep apnea syndrome ascending to 2590 m [23] . Taken together, the findings of the current and cited studies may indicate that hypobaric hypoxia alters sleep structure primarily by affecting the ability to fall asleep and to reach deep sleep stages rather than by fragmenting sleep by frequent apnea/hypopnea-related arousals. Even though the sleep studies at altitude were performed in comfortable, quiet rooms at all locations, we cannot exclude that some alterations in sleep structure were induced by environmental influences other than hypoxia and by psychological factors (excitement), effects that may also be relevant during real-life altitude travel in patients with COPD.
Consistent with the impaired sleep structure, patients estimated to have spent a greater time of the night awake in the first night at 2590 vs. 490 m and their Karolinska sleepiness scale scores indicate a slight reduction in perceived alertness in the morning following the first night at 2590 m (Table 4) . However, this change was of questionable clinical significance and not associated with measurable impairments in the PVT reaction time or in the trail making test performance. The shorter reaction time and the better trail making performance in the morning after the second compared with the first night at 2590 m may be due to learning effects, acclimatization, or other unknown influences. It remains uncertain whether the sleep disturbances recorded in the current study were not sufficient to induce measurable vigilance impairments or whether reductions in alertness or increased sleepiness might have been detected during the altitude sojourns if assessments had been performed in the evenings rather than in the mornings or after a challenge by a monotonous task as in some previous studies that demonstrated increases in the Karolinska scores and in PVT reaction times in healthy individuals after sleep restriction [45, 46] . The increased heart rate at 1650 and 2590 m (Table 2) is consistent with sympathetic excitation due to hypoxemia. This may also explain the higher rate of ventricular extra beats during the first night at 2590 m. The clinical significance of these altitude-related nocturnal arrhythmias remains open. However, the higher rate of nocturnal death in patients with chronic bronchitis and emphysema compared with controls without COPD reported in a study performed near sea level [47] may suggest that sleep induced hypoxemia, in particular, when pronounced due to altitude exposure may represent a risk for patients with COPD going to high altitude.
Conclusions
The results of our randomized crossover trial indicate that patients with moderate to severe COPD experience nocturnal hypoxemia, predominantly central sleep apnea and impairments in sleep duration and structure that are perceived as prolonged time awake during the night and that may result in reduced alertness in the following morning. These findings are important for patients with COPD planning altitude travel and they may help us to design future studies evaluating measures to prevent adverse altitude related health effects in patients with COPD.
